Developing new generation medicines for Central Nervous System (CNS) diseases and disorders with high unmet need

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, including major depressive disorder, neuropathic pain, social anxiety disorder and suicidal ideation.

Our Pipeline

Beyond Current Treatment Options

Focused on providing novel solutions for millions of depression patients with inadequate response to current FDA-approved antidepressants.

Learn More About Ketamine and AV-101

Experienced Leadership

Our experienced leadership team has a proven track record of developing innovative medicines to treat a wide range of CNS diseases and disorders.

Meet Our Team

Stock Information

View Detailed Stock Info
Nasdaq: VTGN Symbol
Day Range
52 Week Range

Email Updates

Be the first to receive news, events & updates Sign Up